Understanding Epidemic Keratoconjunctivitis (EKC)
Epidemic Keratoconjunctivitis (EKC) is a highly contagious eye infection primarily caused by adenoviruses. It affects both the conjunctiva (the membrane lining the eyelids and covering the white part of the eye) and the cornea (the clear front surface of the eye), leading to symptoms such as redness, itching, irritation, light sensitivity, and excessive tearing. While EKC is often self-limiting, lasting typically 2-3 weeks for conjunctival infection and up to a month for corneal involvement, its highly contagious nature can lead to widespread outbreaks, particularly in crowded settings. The Epidemic Keratoconjunctivitis treatment market focuses on alleviating symptoms, preventing complications, and managing its spread.
Current Treatment Approaches and Supportive Care
Currently, there is no specific antiviral treatment with approved effect directly against the adenovirus causing EKC. Treatment primarily focuses on supportive care to manage symptoms and prevent secondary bacterial infections or prolonged discomfort. Common approaches include:
- Cold compresses: To reduce swelling and discomfort.
- Artificial tears: To alleviate dryness and irritation.
- Antihistamine eye drops: To reduce itchiness.
- Antibiotics: Only if bacterial complications are suspected or develop.
- Steroid eye drops: Used cautiously and only under ophthalmologist supervision for severe conjunctival swelling or corneal inflammation, as they can prolong viral shedding or lead to other complications.
Prevention, through strict hygiene practices like frequent handwashing and avoiding sharing personal items, remains crucial to control the spread of EKC.
Market Dynamics and Regional Trends
The Epidemic Keratoconjunctivitis treatment market is influenced by the increasing incidence of EKC outbreaks globally, particularly in crowded areas such as schools, offices, and healthcare facilities. Factors like hygiene levels, contaminated objects, and individual susceptibility impact prevalence. North America is anticipated to acquire a significant market share, around 40%, due to the rising prevalence of the condition, along with government initiatives and increasing research partnerships. The Asia Pacific market is also expected to grow substantially, driven by a shift towards point-of-care healthcare and an increasing number of hospitals in countries like India and China. The global market for EKC treatment was estimated at US$ 500 million in 2023 and is projected to reach US$ 814.45 million by 2033, registering a CAGR of 5%.
Research and Future Outlook
The future of the Epidemic Keratoconjunctivitis treatment market is characterized by ongoing research aimed at developing specific antiviral therapies and improving symptom management. As of now, the most significant unmet need in the market is the lack of a definitive antiviral treatment. However, various startups and pharmaceutical companies are investing in research for ocular disorders, which may eventually lead to targeted solutions for EKC. While the total incident cases of EKC in the 7MM (US, EU5, Japan) were found to be 1,820,868 in 2021, and are expected to go down during the study period (2019–2032), the number of diagnosed incident cases is anticipated to increase, suggesting improved detection. International collaborations and clinical trials are fueling further studies dedicated to EKC management. The market is poised for growth as new formulations and better diagnostic tools emerge, ultimately aiming to provide more effective relief and control over this highly contagious eye infection.
About Market Research Future (MRFR)
Market Research Future (MRFR) is a global market research firm that provides comprehensive insights into market trends, drivers, challenges, and opportunities. We offer a broad range of market intelligence reports and consulting services to help businesses and enterprises in various industries make informed decisions
Media Contact:
Market Research Future (MRFR)
Phone: +1-646-845-9312
